Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7182-7187

  Aldred, Katie J ^a   Breland, Erin J ^a   McPherson, Sylvia A ^c   Turnbough, Charles L ^c   Kerns, Robert J ^d   Osheroff, Neil ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ALANINE; ANTIINFECTIVE AGENT; BACTERIAL DNA; DIVALENT CATION; DNA TOPOISOMERASE INHIBITOR; MANGANESE; MOXIFLOXACIN; NICKEL; PROTEIN SUBUNIT; QUINOLONE DERIVATIVE; RECOMBINANT PROTEIN; VALINE; WATER;

ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS ANTHRACIS; CHEMICAL INTERACTION; CONTROLLED STUDY; CROSS RESISTANCE; DNA CLEAVAGE; DRUG BINDING; DRUG POTENCY; ENZYME METABOLISM; GENE MUTATION; NONHUMAN; WATER METAL ION BRIDGE INTERACTION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; GENETICS; MUTATION; PROTEIN SUBUNIT;

ALANINE; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; CATIONS, DIVALENT; CIPROFLOXACIN; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MANGANESE; MODELS, MOLECULAR; MUTATION; NICKEL; PROTEIN SUBUNITS; RECOMBINANT PROTEINS; TOPOISOMERASE INHIBITORS; VALINE; WATER;

EID: 84912554792     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03734-14     Document Type: Article

References (48)

1. Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X. 2009. Quinolones: action and resistance updated. Curr. Top. Med. Chem. 9:981-998. http://dx.doi.org/10.2174/156802609789630947.
2. Dalhoff A. 2012. Resistance surveillance studies: a multifaceted problem - the fluoroquinolone example. Infection 40:239-262. http://dx.doi .org/10.1007/s15010-012-0257-2.
3. Aldred KJ, Kerns RJ, Osheroff N. 2014. Mechanism of quinolone action and resistance. Biochemistry 53:1565-1574. http://dx.doi.org/10.1021 /bi5000564.
4. Hooper DC. 1999. Mode of action of fluoroquinolones. Drugs 58(Suppl 2):S6 -S10.
5. Anderson VE, Osheroff N. 2001. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr. Pharm. Des. 7:337-353. http://dx.doi.org/10.2174/1381612013398013.
6. Hooper DC. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32(Suppl 1):S9 -S15. http://dx.doi.org /10.1086/319370.
7. Levine C, Hiasa H, Marians KJ. 1998. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta 1400:29-43. http://dx .doi.org/10.1016/S0167-4781(98)00126-2.
8. Champoux JJ. 2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:369-413. http://dx.doi.org/10.1146 /annurev.biochem.70.1.369.
9. Aubry A, Fisher LM, Jarlier V, Cambau E. 2006. First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis. Biochem. Biophys. Res. Commun. 348:158-165. http://dx.doi.org/10.1016/j.bbrc.2006.07.017.
10. Schoeffler AJ, Berger JM. 2008. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q. Rev. Biophys. 41:41-101. http://dx.doi.org/10.1017/S003358350800468X.
11. Deweese JE, Osheroff MA, Osheroff N. 2009. DNA topology and topoisomerases: teaching a "knotty" subject. Biochem. Mol. Biol. Educ. 37:2-10 http://dx.doi.org/10.1002/bmb.20244.
12. Liu Z, Deibler RW, Chan HS, Zechiedrich L. 2009. The why and how of DNA unlinking. Nucleic Acids Res. 37:661-671. http://dx.doi.org/10 .1093/nar/gkp041.
13. Gentry AC, Osheroff N. 2013. DNA topoisomerases: type II, p 163-168. In Lennarz W, Lane M (ed), Encyclopedia of biological chemistry, vol 2 Academic Press, Waltham, MA.
14. Tretter EM, Lerman JC, Berger JM. 2010. A naturally chimeric type IIA topoisomerase in Aquifex aeolicus highlights an evolutionary path for the emergence of functional paralogs. Proc. Natl. Acad. Sci. U. S. A. 107: 22055-22059. http://dx.doi.org/10.1073/pnas.1012938107.
15. Deweese JE, Osheroff N. 2009. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res. 37:738-749. http://dx .doi.org/10.1093/nar/gkn937.
16. Drlica K, Malik M, Kerns RJ, Zhao X. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392. http://dx .doi.org/10.1128/AAC.01617-06.
17. Muñoz R, De la Campa AG. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
18. Pan XS, Ambler J, Mehtar S, Fisher LM. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
19. Pan XS, Fisher LM. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
20. Pan XS, Fisher LM. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2810-2816.
21. Higgins CF, Dorman CJ, Stirling DA, Waddell L, Booth IR, May G, Bremer E. 1988. A physiological role for DNA supercoiling in the osmotic regulation of gene expression in S. Typhimurium and E. coli. Cell 52:569-584. http://dx.doi.org/10.1016/0092-8674(88)90470-9.
22. Yoshida H, Kojima T, Yamagishi J, Nakamura S. 1988. Quinoloneresistant mutations of the gyrA gene of Escherichia coli. Mol. Gen. Genet. 211:1-7. http://dx.doi.org/10.1007/BF00338386.
23. Cullen ME, Wyke AW, Kuroda R, Fisher LM. 1989. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob. Agents Chemother. 33: 886-894. http://dx.doi.org/10.1128/AAC.33.6.886.
24. Drlica K, Zhao X. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
25. Li Z, Deguchi T, Yasuda M, Kawamura T, Kanematsu E, Nishino Y, Ishihara S, Kawada Y. 1998. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinoloneresistant clinical isolates of Staphylococcus epidermidis. Antimicrob. Agents Chemother. 42:3293-3295.
26. Price LB, Vogler A, Pearson T, Busch JD, Schupp JM, Keim P. 2003. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob. Agents Chemother. 47: 2362-2365. http://dx.doi.org/10.1128/AAC.47.7.2362-2365.2003.
27. Bast DJ, Athamna A, Duncan CL, de Azavedo JC, Low DE, Rahav G, Farrell D, Rubinstein E. 2004. Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. J. Antimicrob. Chemother. 54:90-94. http://dx.doi.org/10.1093/jac/dkh294.
28. Grohs P, Podglajen I, Gutmann L. 2004. Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations. Antimicrob. Agents Chemother. 48:3024-3027. http://dx.doi.org/10.1128/AAC.48.8.3024-3027.2004.
29. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L. 2009. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 53:235-241. http://dx .doi.org/10.1128/AAC.00665-08.
30. Yang J, Luo Y, Li J, Ma Y, Hu C, Jin S, Ye L, Cui S. 2010. Characterization of clinical Escherichia coli isolates from China containing transferable quinolone resistance determinants. J. Antimicrob. Chemother. 65: 453-459. http://dx.doi.org/10.1093/jac/dkp478.
31. Lautenbach E, Metlay JP, Mao X, Han X, Fishman NO, Bilker WB, Tolomeo P, Wheeler M, Nachamkin I. 2010. The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin. Infect. Dis. 51:280-285. http: //dx.doi.org/10.1086/653931.
32. Bansal S, Tandon V. 2011. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates. Int. J. Antimicrob. Agents 37:253-255. http://dx.doi.org/10 .1016/j.ijantimicag.2010.11.022.
33. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD. 2010. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 17: 1152-1153. http://dx.doi.org/10.1038/nsmb.1892.
34. Aldred KJ, McPherson SA, Wang P, Kerns RJ, Graves DE, Turnbough CL, Jr, Osheroff N. 2012. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry 51:370-381. http://dx.doi.org/10.1021/bi2013905.
35. Aldred KJ, McPherson SA, Turnbough CL, Jr, Kerns RJ, Osheroff N. 2013. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res. 41:4628-4639. http://dx.doi.org/10.1093/nar/gkt124.
36. Aldred KJ, Schwanz HA, Li G, McPherson SA, Turnbough CL, Jr, Kerns RJ, Osheroff N. 2013. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. ACS Chem. Biol. 8:2660-2668. http://dx.doi.org/10.1021 /cb400592n.
37. Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, de Azavedo JC. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44: 3049-3054. http://dx.doi.org/10.1128/AAC.44.11.3049-3054.2000.
38. Dong S, McPherson SA, Wang Y, Li M, Wang P, Turnbough CL, Jr, Pritchard DG. 2010. Characterization of the enzymes encoded by the anthrose biosynthetic operon of Bacillus anthracis. J. Bacteriol. 192:5053-5062. http://dx.doi.org/10.1128/JB.00568-10.
39. Malik M, Marks KR, Mustaev A, Zhao X, Chavda K, Kerns RJ, Drlica K. 2011. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 55:2335-2343. http://dx.doi.org/10.1128/AAC.00033-11.
40. Fortune JM, Osheroff N. 1998. Merbarone inhibits the catalytic activity of human topoisomerase II by blocking DNA cleavage. J. Biol. Chem. 273:17643-17650. http://dx.doi.org/10.1074/jbc.273.28.17643.
41. Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N. 2011. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry 50:3240-3249. http://dx.doi.org/10.1021/bi200094z.
42. Yoshida H, Bogaki M, Nakamura M, Nakamura S. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272. http://dx.doi.org/10 .1128/AAC.34.6.1271.
43. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35:1647-1650. http://dx .doi.org/10.1128/AAC.35.8.1647.
44. Zhou J, Dong Y, Zhao X, Lee S, Amin A, Ramaswamy S, Domagala J, Musser JM, Drlica K. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525. http://dx.doi.org/10.1086/315708.
45. Laponogov I, Pan XS, Veselkov DA, McAuley KE, Fisher LM, Sanderson MR. 2010. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One 5:e11338. http://dx.doi.org/10.1371 /journal.pone.0011338.
46. Pan XS, Gould KA, Fisher LM. 2009. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob. Agents Chemother. 53:3822-3831. http://dx .doi.org/10.1128/AAC.00113-09.
47. Oppegard LM, Streck KR, Rosen JD, Schwanz HA, Drlica K, Kerns RJ, Hiasa H. 2010. Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones. Antimicrob. Agents Chemother. 54:3011-3014. http: //dx.doi.org/10.1128/AAC.00190-10.
48. Huband MD, Cohen MA, Zurack M, Hanna DL, Skerlos LA, Sulavik MC, Gibson GW, Gage JW, Ellsworth E, Stier MA, Gracheck SJ. 2007. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups. Antimicrob. Agents Chemother. 51:1191-1201. http: //dx.doi.org/10.1128/AAC.01321-06.